Quick Answer
Scinai Immunotherapeutics Ltd. reported Operating Income of -$8.64 million for fiscal year 2024.
Scinai Immunotherapeutics Ltd. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$8.64M | +11.0% |
| 2023 | -$9.71M | +12.3% |
| 2022 | -$11.06M | -1.8% |
| 2021 | -$10.86M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | -$3.19M | -21.8% | -21.8% |
| March 31, 2022 | -$2.62M | — | — |
- Scinai Immunotherapeutics Ltd. showed an increase of +11.0% in Operating Income compared to the prior fiscal year.
- Over the 2021–2024 period, Scinai Immunotherapeutics Ltd.’s operating income has grown by 20.5% (from -$10.86 million to -$8.64 million).
- The most recent figure is from Scinai Immunotherapeutics Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on May 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: